Anti‐phospholipid syndrome (APS) is characterized by arterial and/or venous thrombosis and pregnancy morbidity associated with the presence of “anti‐phospholipid antibodies.” Thrombosis may be the result of a hypercoagulable state related… Click to show full abstract
Anti‐phospholipid syndrome (APS) is characterized by arterial and/or venous thrombosis and pregnancy morbidity associated with the presence of “anti‐phospholipid antibodies.” Thrombosis may be the result of a hypercoagulable state related to activation of endothelial cells and platelets by anti‐β2‐glycoprotein I (β2‐GPI) antibodies. Anti‐β2‐GPI antibodies induce a proinflammatory and procoagulant phenotype in these cells that, after activation, express tissue factor (TF), the major initiator of the clotting cascade, playing a role in thrombotic manifestations. Moreover, TF expression may also be induced by heparanase, an endo‐β‐D‐glucuronidase, that generates heparan sulfate fragments, regulating inflammatory responses.
               
Click one of the above tabs to view related content.